Prostate cancer remains the second most common malignancy diagnosed in men worldwide, with global incidence now exceeding 1.4 million new prostate cancer cases a year. For decades, the diagnostic pathway leaned on a blunt instrument: a 12-core systematic biopsy taken largely by anatomical guesswork. That era is closing. Fusion biopsy, which overlays high-resolution MRI data onto real-time ultrasound to guide the needle directly into suspicious tissue, has moved from a niche academic technique to a standard-of-care diagnostic in leading urology centers.
The numbers tell the story plainly. In a large 1,229-patient cohort stratified by PI-RADS score, MRI-ultrasound fu...
